Detalles de la búsqueda
1.
The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets.
J Pharmacol Sci
; 152(3): 193-199, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37257947
2.
Anti-parkinsonian activity of the adenosine A2A receptor antagonist/inverse agonist KW-6356 as monotherapy in MPTP-treated common marmosets.
Eur J Pharmacol
; 950: 175773, 2023 Jul 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37146707
3.
The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
Eur J Pharmacol
; 766: 25-30, 2015 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26415982
4.
The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Eur J Pharmacol
; 747: 160-5, 2015 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25499739
Resultados
1 -
4
de 4
1
Próxima >
>>